[1] [1] HAYNES L D, JULLIARD W A, MEZRICH J D, et al. Specific donor?HLA-DR types correlate with altered susceptibility to development of chronic lung allograft dysfunction［J］. Transplantation, 2018, 102(7): 1132-1138.

[3] [3] OGURA K, CECKA J. Cadaver retransplants［J］. Clinical Transplantation, 1990, 4: 471-483.

[4] [4] ANGLICHEAU D, MUTHUKUMAR T, HUMMEL A, et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis［J］. Transplantation, 2012, 93(11): 1136-1146.

[5] [5] CHANG C T, WANG G J, KUO C C, et al. Electronegative low-density lipoprotein increases coronary artery disease risk in uremia patients on maintenance hemodialysis［J］. Medicine (Baltimore), 2016, 5(2): e2265.

[6] [6] MARRARI M, CONCA R, PRATICO-BARBATO L, et al. Brief report: why did two patients who type for HLA-B13 have antibodies that react with all Bw4 antigens except HLA-B13? ［J］Transplant Immunology, 2011, 25(4): 217-220.

[7] [7] TERASAKI P I. Humoral theory of transplantation［J］. American Journal of Transplantation, 2003, 3(6): 665-673.

[8] [8] EL-AWAR N, TERASAKI P, LAZDA V. et al. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies［J］. Transplantation Proceedings, 2002, 34(7): 2531-2532.

[9] [9] EL-AWAR N, LEE J H, TARSITANI C, et al. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens［J］. Human Immunology, 2007, 68(3): 170-180.

[10] [10] PEI R, LEE J H, SHIH N J, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities［J］. Transplantation, 2003, 75(1): 43-49.

[11] [11] DUQUESNOY R J. HLA epitope based matching for transplantation［J］. Transplant Immunology, 2014, 31(1): 1-6.

[12] [12] WIEBE C, POCHINCO D, BLYDT-HANSEN T D, et al. Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes［J］. American Journal of Transplantation, 2013, 13(12): 3114-3122.

[13] [13] WALTON D C, HIHO S J, CANTWELL L S, et al. HLA matching at the eplet level protects against chronic lung allograft dysfunction［J］. American Journal of Transplantation, 2016, 16(9): 2695-2703.

[14] [14] EL-AWAR N, JUCAUD V, NGUYEN A. HLA epitopes: the targets of monoclonal and alloantibodies defined［J］. Journal of Immunology Research, 2017, 2017: 3406230.

[15] [15] SASAKI N, IDICA A, TERASAKI P. Is there a differential strength of specific HLA mismatches in kidney transplants?［J］. Transplantation Proceedings, 2008, 40(4): 1091-1094.

[16] [16] OPELZ G, DOHLER B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades［J］. Transplantation, 2007, 84(2): 137-143.

[17] [17] MATTHEW S, JOSHUA K, STEVE H, et al. HLA epitope matching in kidney transplantation: an overview for the general nephrologist［J］. American Journal of Kidney Diseases, 2018, 71(5): 720-731.

[18] [18] TERASAKI P I, OZAWA M. Predicting kidney graft failure by HLA antibodies: a prospective trial［J］. American Journal of Transplantation, 2004, 4(3): 438-443.

[19] [19] PORCHERAY F, WONG W, SAIDMAN S L. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans［J］. American Journal of Transplantation, 2009, 9(9): 2126-2135.

[20] [20] DUQUESNOY R J. HLAMmatchmaker: a molecularly based donor selection algorithm for highly alloimmunized patients［J］. Transplant Proceedings, 2001, 33(1/2) : 493-497.

[21] [21] ROBERT C, GERHARD O, CHELSEA J, et al. The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors［J］. Transplantation, 2016, 100(5): 1094-1102.